Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells $369,740.80 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 7,040 shares of the company’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $52.52, for a total value of $369,740.80. Following the completion of the transaction, the chief executive officer owned 73,320 shares of the company’s stock, valued at $3,850,766.40. The trade was a 8.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.68, for a total value of $556,300.80.
• On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.66, for a total value of $272,764.80.
• On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.91, for a total transaction of $258,244.80.
• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $53.73, for a total transaction of $378,259.20.
• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.37, for a total transaction of $361,644.80.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.42, for a total transaction of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.40, for a total transaction of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.96, for a total transaction of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.62, for a total transaction of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.81, for a total transaction of $3,005,705.34.

Phibro Animal Health Stock Performance

NASDAQ PAHC opened at $50.76 on Friday. The company has a 50-day simple moving average of $47.57 and a two-hundred day simple moving average of $42.79. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. Phibro Animal Health Corporation has a 12-month low of $16.16 and a 12-month high of $56.30. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 0.78 and a beta of 0.74.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The firm had revenue of $373.91 million for the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, equities analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Wednesday, March 4th. Phibro Animal Health’s payout ratio is 21.33%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PAHC. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a report on Friday, February 6th. Finally, Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $37.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PAHC. Millennium Management LLC increased its stake in shares of Phibro Animal Health by 4,227.1% during the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after buying an additional 626,492 shares during the period. Capricorn Fund Managers Ltd purchased a new stake in Phibro Animal Health in the third quarter worth $10,233,000. JPMorgan Chase & Co. lifted its stake in Phibro Animal Health by 1,730.9% in the third quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock worth $9,634,000 after acquiring an additional 225,110 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in Phibro Animal Health in the third quarter valued at $8,931,000. Finally, Ranger Investment Management L.P. boosted its holdings in Phibro Animal Health by 101.1% in the second quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock valued at $9,143,000 after acquiring an additional 179,975 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.